Nebido (testosterone undecanoate depot injection)
/ Bayer, Grunenthal
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
223
Go to page
1
2
3
4
5
6
7
8
9
August 15, 2026
Effect of Testosterone Treatment on Leucocyte Telomere Length in Men: Results From a Randomised Placebo-Controlled Trial.
(PubMed, Andrology)
- P3 | "There was no effect of testosterone treatment on telomere length in this group of men. Larger studies with longer treatment durations are merited."
Journal • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
June 23, 2026
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
(clinicaltrials.gov)
- P2 | N=240 | Recruiting | Sponsor: Seattle Institute for Biomedical and Clinical Research | Active, not recruiting ➔ Recruiting
Enrollment open • Endocrine Disorders • Fatigue • Oncology
June 20, 2026
Testosterone therapy in boys with constitutional delay of growth and puberty: a PubMed-based systematic review and exploratory meta-analysis.
(PubMed, Clin Exp Pediatr)
- "Across formulations (intramuscular testosterone enanthate or cypionate, depot ester mixtures, oral testosterone undecanoate, and transdermal gel), the literature consistently showed greater short-term height velocity and more rapid pubertal progression in treated boys without a clinically meaningful adverse effect on near-adult height when conservative regimens were used. Testosterone therapy in boys with CDGP was associated with faster short-term growth and pubertal maturation, and long-term data did not show a detrimental effect on near-adult height when conservative time-limited regimens were used. The quantitative evidence base is small and methodologically heterogeneous, and modern multicenter randomized trials incorporating validated patient-reported outcomes and long-term follow-ups are necessary."
Journal • Retrospective data • CNS Disorders • Endocrine Disorders • Pediatrics
June 20, 2026
Effect of testosterone addition to nutrition and exercise on muscle mass in men with cirrhosis: the next trial.
(PubMed, Hepatol Int)
- "The addition of testosterone therapy to nutrition and structured exercise protocols significantly improves the appendicular muscle mass, reduces frailty and need of rehospitalization in cirrhosis patients with sarcopenia and frailty."
Journal • Fibrosis • Hepatology • Immunology • Sarcopenia • Transplantation
June 02, 2026
Multiple Focal Nodular Hyperplasia in A Transgender Man
(ENDO 2026)
- "After discontinuation of therapy, testosterone undecanoate was reintroduced at age 34... This case highlights the relevance of testosterone's pharmacokinetics and tissue-level effects in the evaluation of hepatic lesions in transgender individuals. The choice of formulation and route of administration is critical for minimizing hepatic risk and guiding long-term therapy."
Cholestasis • Hepatocellular Cancer • Hepatology • Solid Tumor
May 12, 2026
Effects of 4 Years Testosterone Treatment on Glycemia, Anthropometry, Sexual Function and Safety
(ENDO 2026)
- "Eligible and consenting participants (n=121) continued their original masked allocation to intramuscular testosterone undecanoate (1000mg 3 monthly) or placebo...Wittert, G. et al. Lancet Diabetes Endocrinol 9, 32-45 (2021)."
Clinical • Metabolic Disorders • Type 2 Diabetes Mellitus
April 07, 2026
Effect of testosterone supplementation on muscle strength and physical function after bariatric surgery - A randomized placebo-controlled study
(ECO 2026)
- "Testosterone supplementation did not preserve muscle strength nor physical functionality in men with hypogonadism undergoing bariatric surgery. Dropouts may have influenced statistical power. Conflicts of Interest: None Disclose Funding: Research relating to this abstract was funded by the fund of strategic clinical research in the Region of Southern Denmark."
Bariatric surgery • Clinical • Surgery • Endocrine Disorders • Genetic Disorders • Obesity
April 23, 2026
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
(clinicaltrials.gov)
- P2 | N=240 | Active, not recruiting | Sponsor: Seattle Institute for Biomedical and Clinical Research | Recruiting ➔ Active, not recruiting
Enrollment closed • Endocrine Disorders • Fatigue • Oncology
April 16, 2026
Effects of Testosterone-Augmented Multimodal Exercise Intervention in Spinal Cord Injury: A Randomized Controlled Trial.
(PubMed, J Clin Endocrinol Metab)
- "A home-based multimodality intervention combining FES-LC, AE, and testosterone was safe and associated with greater improvements in lean mass and hemoglobin. Although between-group differences in aerobic capacity were not statistically significant, greater within-group increases were observed in the multimodality group. These findings may inform future studies of testosterone-augmented exercise interventions for individuals living with SCI."
Journal • CNS Disorders • Hematological Disorders • Metabolic Disorders • Muscular Atrophy • Orthopedics
April 13, 2026
TOTEM-RRMS: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Multiple Sclerosis
April 07, 2026
Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency
(clinicaltrials.gov)
- P2 | N=96 | Not yet recruiting | Sponsor: Rune Skovgaard Rasmussen
New P2 trial • Geriatric Disorders
March 09, 2026
Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
(PubMed, Minerva Endocrinol (Torino))
- "Our preliminary findings suggest that adding TRT to tirzepatide in late tirzepatide responders who are hypogonadal may optimize weight loss quality, prevent muscle depletion, and restore sexual and metabolic health. This dual pharmacological approach represents a promising precision medicine strategy for managing complex phenotypes of male obesity-associated hypogonadism."
Journal • Endocrine Disorders • Genetic Disorders • Obesity • Sarcopenia
March 10, 2026
Simple and sensitive cellulose paper-based microextraction of 25 steroid esters from human serum/plasma for doping control purposes.
(PubMed, Anal Bioanal Chem)
- "The analytical workflow was qualitatively validated according to the UNI CEI EN ISO/IEC 17025 standard and the WADA technical rules and notes in terms of selectivity (target analytes were distinguishable from the matrix interferences), sensitivity (limits of detection in the range of 0.05-0.70 ng/mL), carry-over (no signals were detected in the negative sample injected after the positive sample), intra and inter-day stability of the retention times (≤0.5%), matrix effect (13-32%), extract stability (the target analytes were stable for at least 72 h in the autosampler at 10 °C), and extraction yield (43-88%). Plasma samples collected after testosterone undecanoate injection were finally analyzed: the compound was detectable in all three volunteers evaluated for at least 1 month after administration, demonstrating the effectiveness of the newly developed method for doping control purposes."
Journal
March 07, 2026
Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?
(clinicaltrials.gov)
- P2/3 | N=45 | Completed | Sponsor: Norwegian School of Sport Sciences | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025
Trial completion • Trial completion date • Trial primary completion date • Sarcopenia
February 27, 2026
Easing the burden: exploring the role of long-acting testosterone formulations in gender-affirming care.
(PubMed, Front Public Health)
- "Although not FDA approved in the United States for gender dysphoria, testosterone undecanoate is a long-acting testosterone formulation administered every 10 weeks...Although there are no official guidelines recommending short versus long-acting testosterone use, having the availability of long-acting formulations may create space for shared decision-making between patients and providers to best address gender-affirming goals of patients. Barriers may exist in terms of paying for and acquiring long-acting formulations, making a dedicated pharmacy technician or insurance authorization specialist a critical part of a gender health program."
Journal • CNS Disorders
January 03, 2026
From venipuncture to self-sampling dried blood spots: a shift in monitoring testosterone levels.
(PubMed, Clin Chem Lab Med)
- "At-home DBS sampling is a feasible and reliable method for monitoring testosterone in patients treated with intramuscular testosterone undecanoate, improving patient comfort and convenience. However, DBS sampling at-home is currently unsuitable for patients using testosterone gel, likely due to contamination issues. Comprehensive patient education on collection of DBS samples is crucial to ensure high-quality DBS and accurate testosterone quantification."
Journal
November 11, 2025
Cost-Utility of Intramuscular Testosterone for Men and Male Adolescents With Organic Hypogonadotropic Hypogonadism in Brazil
(ISPOR-EU 2025)
- "For adults, the ICERs for the three approved formulations were: R$ 4,044.41/QALY for testosterone blend (decanoate, phenylpropionate, isocaproate, propionate); R$ 9,146.67/QALY for testosterone cypionate; R$ 5,201.39/QALY for testosterone undecanoate. Our results show that TRT is cost-effective for the management of OHH, supporting their inclusion in the minimum benefit list of Brazilian SUS."
HEOR • Endocrine Disorders
October 31, 2025
Efficacy and Safety of Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Prospective, Multicenter, Double-Blind, Randomized Controlled Clinical Study
(ChiCTR)
- P=N/A | N=96 | Not yet recruiting | Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
New trial • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • ASXL1 • SF3B1
October 02, 2025
Evaluation of endogenous steroid sulfates and glucuronides in urine after oral and transdermal administration of testosterone. Part I: male participants.
(PubMed, J Steroid Biochem Mol Biol)
- "Sulfate ratios indicated higher sensitivity to multiple administrations of testosterone undecanoate (TU) tablets and T gel, significantly prolonging detection times compared to conventional steroid profile biomarkers...These findings provide further evidence that incorporating sulfate EAAS metabolites into steroid profiling enhances detection capabilities. For advanced T doping detection, sulfate metabolites should be considered essential biomarkers in the steroid profile."
Journal
September 16, 2025
An 8-Week Virtual Exercise Environment Intervention for People Post-Stroke: A Longitudinal Mixed Methods Single Case Study.
(PubMed, Inquiry)
- "The device, environment, and intervention were rated as usable, and the participant attributed several functional improvements with his paretic arm to the program. The AVEED, combined with an exergaming platform, was successful in improving the cycling speed and paretic arm contribution of an individual post-stroke through an 8-week non-immersive virtual exercise environment program."
Journal • Cardiovascular
June 30, 2025
TOTEM-RRMS: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Jan 2027 ➔ Dec 2027 | Trial primary completion date: Jan 2027 ➔ Dec 2027
Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis
June 21, 2025
Recognition, prevalence and prevention of falsely high serum testosterone concentrations in testosterone gel users.
(PubMed, Clin Chim Acta)
- "Testosterone contamination of blood samples is rather common among testosterone gel users, and can be recognized by an increased T/E ratio. To prevent testosterone contamination, application of testosterone gel especially at the venipuncture site should be avoided. Clinicians and laboratory specialists should stay attentive to this common form of contamination and instruct patients accordingly."
Journal
April 10, 2025
From venipuncture to self-sampling DBS: a shift in monitoring testosterone levels
(ESPE-ESE 2025)
- "For patients receiving trt via deeply intramuscular testosteroneundecanoate injection, monitoring testosterone levels via DBS sampling at home is feasible, enhancing patient comfort and convenience. Patient education is needed to ensure proper collection of DBS samples, leading to high quality DBS and accurate testosterone quantification."
Cardiovascular
April 30, 2025
Self-injection experiences among transgender people on injectable gender-affirming hormone therapy: a narrative review.
(PubMed, J Am Pharm Assoc (2003))
- "Based on the types of injection-related challenges identified, pharmacists, as one of the most accessible health care providers in the United States, are well-positioned to intervene and improve the experience of patients using injectable GAHT."
Journal • Review • Pain
April 27, 2025
Exercise Heart Rate Variability Suggests Parasympathetic Hyperactivity during Simulated Military Operations Irrespective of Testosterone Administration.
(PubMed, Med Sci Sports Exerc)
- "Exercise HRV metrics suggested parasympathetic hyperactivity despite concomitant increases in stress across the extended simulated military operations. A single dose of testosterone undecanoate does not appear to negatively affect the autonomic response to high stress in young health physically active males."
Journal
1 to 25
Of
223
Go to page
1
2
3
4
5
6
7
8
9